← Scroll for more →
Catalyst Pharmaceuticals, Inc. (CPRX)
Pharmaceutical Preparations
Latest Price
$31.49
TTM P/E
18.20
Normalized P/E
28.57
Div Yield
--
Book Value
8.28
P/B Ratio
3.80
Valuation metrics
adjust assumptions →EPS: $1.68
Book value / share: $7.79
Formula: √(22.5 × EPS × BVPS)
Graham Number
$17.16
46% downside
Norm. op. income: $87M (median of 7yr)
Tax rate: 24%
Discount rate: 10%
Growth assumption: zero (EPV is a no-growth value)
Earnings Power Value
$11.15
65% downside
Base FCF: $143M (median of recent 5yr)
Growth: 25%/yr (median YOY, capped at 25%)
Discount rate: 10%
Terminal growth: 3%
Projection horizon: 10 years
DCF Fair Value
$92.88
+195% upside
EPS: $1.68
Target P/E: 29×
Formula: EPS × P/E
P/E Fair Value
$48.72
+55% upside
Institutional Ownership
87.7% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| BlackRock, Inc. | 19.16M | $602.0M | 15.68% | +384.3K | 2026-06-30 |
| State Street Corp | 7.63M | $239.0M | 6.24% | +764.0K | 2026-06-30 |
| American Century Companies Inc | 5.55M | $174.0M | 4.55% | +1.42M | 2026-06-30 |
| Vanguard Capital Management LLC | 5.14M | $161.0M | 4.20% | +12.7K | 2026-06-30 |
| Dimensional Fund Advisors LP | 3.63M | $114.0M | 2.97% | +204.6K | 2026-06-30 |
| Glazer Capital, LLC | 3.60M | $113.0M | 2.95% | -- | 2026-06-30 |
| JPMorgan Chase & Co | 3.17M | $99.0M | 2.59% | +2.80M | 2026-06-30 |
| Geode Capital Management, LLC | 3.15M | $99.0M | 2.58% | +177.9K | 2026-06-30 |
| Hbk Investments L P | 2.82M | $88.0M | 2.31% | -- | 2026-06-30 |
| Morgan Stanley | 2.76M | $86.0M | 2.26% | +73.1K | 2026-06-30 |